Andere Sprachen Qurient Co., Ltd.

Aktien

A115180

KR7115180002

A115180

Schlusskurs Korea S.E. Andere Börsenplätze 00:00:00 19.06.2024			% 5 Tage	% 1. Jan.
3.710 ^KRW	+4,95 %		-3,26 %	-20,56 %

21.05.	Qurient Therapeutics schließt CRADA mit dem National Cancer Institute ab, um an einer klinischen Phase 1/2 Studie von Q901 in Kombination mit TROP2-ADC mitzuwirken	CI
2023	Qurient Co., Ltd. meldet Ergebnis für das erste Quartal zum 31. März 2023	CI

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Qurient Therapeutics Enters CRADA with the National Cancer Institute to Collaborate on a Phase 1/2 Clinical Study of Q901 in Combination with TROP2-ADC	21.05.
Qurient Co., Ltd. announced that it has received KRW 13.499996307 billion in funding from DongKoo Bio & Pharma Co., Ltd.	17.05.
Qurient Co., Ltd. announced that it expects to receive KRW 13.499998256 billion in funding from DongKoo Bio & Pharma Co., Ltd. and another investor	12.04.
Qurient Co., Ltd. announced that it has received KRW 5.999997188 billion in funding from Premier Partners, LLC	27.12.
Qurient Co., Ltd. announced that it expects to receive KRW 5.99999268 billion in funding from Premier Partners, LLC	19.12.
Qurient Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	12.05.23
Qurient Co. Ltd. and TB Alliance Announces Exclusive License Agreement for Telacebec	03.02.23
Qurient Co., Ltd. Announces Dosing of First Patient in Q702 in Combination with KEYTRUDA® in a Phase 1b/2 Clinical Study for the Treatment of Patients with Solid Tumors	31.01.23
Qurient Co. Ltd Announces Dosing of First Patient in Q901 Phase 1/2 Clinical Study for the Treatment of Patients with Solid Tumors	01.12.22
Qurient Announces Dosing of First Patient in Q901 Phase 1/2 Clinical Study for the Treatment of Patients with Solid Tumors	01.12.22
Qurient Co., Ltd. Enters into A Clinical Collaboration Agreement with Merck & Co., Inc. for Clinical Study of Q901	14.09.22
Qurient Co. Ltd. U.S. FDA Clearance of IND Application for Q901, a Novel Cancer Therapy	08.02.22
Qurient Co., Ltd. announced that it has received KRW 12.5 billion in funding from CureBio Co.,Ltd., and other investors	17.12.21
Qurient Co., Ltd. announced that it expects to receive KRW 12.5 billion in funding from CureBio Co.,Ltd., and other investors	09.12.21
Qurient Co. Ltd. Enters into A Clinical Collaboration Agreement with MSD	23.11.21
Qurient Co., Ltd.(KOSDAQ:A115180) dropped from S&P Global BMI Index	07.07.21
Qurient Co., Ltd. Enrolls First Patient in Q702 U.S. Phase 1 Study	26.01.21
Qurient Co., Ltd. announced that it expects to receive KRW 59.99986805 billion in funding from a group of investors	22.09.20
QLi5 Therapeutics GmbH announced that it expects to receive KRW 2.039115 billion in funding from Qurient Co., Ltd.	11.06.20
Qurient Co., Ltd. Announces U.S. FDA Clearance of IND Application for Q702	26.05.20

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Qurient Co., Ltd.

Aktien

A115180

KR7115180002

A115180

Andere Sprachen

Filter